Ohm Laboratories Recalls Loratadine Tablets for Out-of-Specification Assay
Ohm Laboratories is recalling Premier Value Loratadine Orally Disintegrating Tablets because an assay test result was out of specification.
The agency’s classification
FDA (Drugs): Class III
Class III is a situation in which use of or exposure to a violative product is not likely to cause adverse health consequences.
This is the agency’s own classification, taken from its notice. The severity score below is our assessment, not the agency’s. How recall classes work
What this means for you
Our assessment, not the agency’s: severity 2/5 (Moderate).
Minor labeling or packaging issue, or a voluntary precautionary recall. Risk of harm is low but real — follow the manufacturer's instructions.
Our severity reasoning: The recall is classified as FDA Class III, which indicates a low risk of adverse health consequences. The hazard is a quality control issue (out-of-specification assay) without reported injuries or illnesses.
Plain-English summary
Ohm Laboratories, Inc. is recalling Premier Value Loratadine Orally Disintegrating Tablets, USP, 10 mg, 30-count tablets per box. The recall is due to an out-of-specification (OOS) result for the assay test, which measures the amount of active ingredient in the drug product.
The affected product is distributed by Chain Drug Consortium. The recall involves 11,232 boxes distributed nationwide. The specific batch numbers are 2600126 (Exp 2/29/2016) and 2644273 (Exp 9/30/2016).
Consumers should check their medication for these specific batch numbers and expiration dates. If the product matches the recalled description, consumers should stop using it and contact their pharmacist or the recalling firm for instructions on how to return or dispose of the medication.
The recalled product
- Product
- Premier Value Loratadine Orally Disintegrating Tablets, USP, 10 mg, 30-count tablets per box; Distributed by Chain Drug Consortium, 3301 NW Boca Raton Blvd. Suite 101, Boca Raton, FL 33431, NDC 68016-527-31, UPC 8 4098601899 2
- Manufacturer
- Ohm Laboratories, Inc.
- Category
- Drug — Antihistamine
- Affected units
- 11,232
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (4)
- Batch Numbers: 2600126
- Exp 2/29/2016
- 2644273
- Exp 9/30/2016
Distribution
Distributed nationwide across the United States.
Part of a larger recall action
This product is one of 21 recalled by Ohm Laboratories, Inc. under a single FDA (Drugs) recall action. The agency files each product separately, so the size of the action is not visible from this page alone.
See all 21 products in this recall →Related recalls
Same manufacturer · Ohm Laboratories, Inc.
See all →- ModerateOhm Allergy Relief Loratadine Recalled for Out-of-Specification Assay
FDA (Drugs) · 2015-10-21
- ModerateQC Quality Choice Loratadine Tablets Recalled for Out-of-Specification Assay
FDA (Drugs) · 2015-10-21
- LowCVS Loratadine Tablets Recalled for Out-of-Specification Assay Results
FDA (Drugs) · 2015-10-21
- ModerateOhm Laboratories Recalls Loratadine Tablets Due to Potency Issues
FDA (Drugs) · 2015-10-21
- ModerateOhm Laboratories Recalls Loratadine Tablets Due to Out-of-Specification Assay
FDA (Drugs) · 2015-10-21
Same hazard · quality control
See all →- HighBaxter Recalls CARDENE IV Nicardipine Injection Due to Manufacturing Deviations
FDA (Drugs) · 2026-09-09
- SevereBaxter Recalls Clindamycin Injection Due to Manufacturing Deviations
FDA (Drugs) · 2026-09-09
- ModerateMylan Recalls Mycophenolate Mofetil Injection Due to Dissolution Failures
FDA (Drugs) · 2026-09-09
- HighBaxter Recalls MYXREDLIN Insulin Due to Manufacturing Deviations
FDA (Drugs) · 2026-09-09
- HighBaxter Recalls Vasopressin Injection Due to Manufacturing Deviations
FDA (Drugs) · 2026-09-09
Similar recalls
- LowOhm Recalls Loratadine Tablets Due to Out-of-Specification Assay
FDA (Drugs) · 2015-06-24
- ModerateOhm Laboratories Recalls Loratadine and Pseudoephedrine Sulfate Tablets Due to Blister Defects
FDA (Drugs) · 2014-04-30
- ModerateApotex Recalls Olanzapine Tablets Due to Subpotent Drug Levels
FDA (Drugs) · 2014-10-01
- LowDr. Reddy's Recalls Olanzapine Tablets Due to Impurity Specification Failure
FDA (Drugs) · 2017-02-15
- LowApotex Recalls Subpotent Olanzapine Orally Disintegrating Tablets
FDA (Drugs) · 2015-05-20
- HighLosartan Potassium Tablets Recalled for Elevated AZIDO Impurity Levels
FDA (Drugs) · 2022-07-06